In CRC–CAF co-culture systems (SW480 + CAF and HCT116 + CAF), treatment with the SMYD3 methyltransferase inhibitor BCI-121 or the Src kinase inhibitor SU6656 (a canonical CDCP1 effector) significantly reduced CAF transcripts of α-SMA, FAP, PDGFRβ, and S100A4 relative to DMSO (Figure 6A). The gene discussed is SMYD3; the disease is colorectal carcinoma.